Condition (MeSH)
Pulmonary Atresia
ClinicalTrials.gov lists 9 trials for Pulmonary Atresia or a narrower condition beneath it. Edwards Lifesciences has the most among industry and government lead sponsors, with 2.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials per phase
9 of the 9 trials are tagged with Pulmonary Atresia itself; the rest are tagged with a narrower condition beneath it.
When did Pulmonary Atresia trials start? (9)
Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Trials over time, by phase
- Not applicable
- Observational
Top of scale: 1
Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.
| Year | Trials started |
|---|---|
| 2025 | 1 |
| 2023 | 1 |
| 2022 | 1 |
| 2019 | 1 |
| 2017 | 1 |
| 2016 | 1 |
| 2015 | 1 |
| 2006 | 1 |
| 1995 | 1 |
No forecast is made for this condition: it averages 0.6 trial starts a year over the five years to September, under the 5 a year the method needs.
Recruitment duration, a model prediction: 2 trials still running at the 2026-10-09 snapshot, fewer than the 5 needed for a median. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
What phase are Pulmonary Atresia trials in? (2)
Shown in this order: phase order.
Show the trials by phase as a table
| Phase | Trials |
|---|---|
| Not applicable | 3 |
| Observational | 6 |
How many Pulmonary Atresia trials are recruiting? (2)
Shown in this order: the order a trial moves through, from not yet recruiting to unknown.
| Status | Trials |
|---|---|
| Recruiting | 5 |
| Completed | 4 |
Status as registered on ClinicalTrials.gov. Each trial is counted once.
Which lead sponsors run the most Pulmonary Atresia trials? (3)
Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.
| Sponsor | Trials |
|---|---|
| Edwards Lifesciences | 2 |
| National Center for Research Resources (NCRR) | 1 |
| PECA Labs | 1 |
Which publications cover Pulmonary Atresia? (14)
Shown in this order: major-topic papers first, then newest, then most linked to trials.
| Publication | Journal | Year | Major topic |
|---|---|---|---|
| Pulmonary Atresia, Ventricular Septal Defect, and Major Aortopulmonary Collateral Arteries: The Natural History and Late Presentation. | World journal for pediatric & congenital heart surgery | 2025 | Yes |
| The American Association for Thoracic Surgery (AATS) 2022 Expert Consensus Document: Management of infants and neonates with tetralogy of Fallot. | The Journal of thoracic and cardiovascular surgery | 2023 | Yes |
| A novel approach to neonatal management of tetralogy of Fallot, with pulmonary atresia, and multiple aortopulmonary collaterals. | JACC. Cardiovascular imaging | 2015 | Yes |
| Establishment of right ventricle-pulmonary artery continuity as the first-stage palliation in older infants with pulmonary atresia with ventricular septal defect may be preferable to use of an arterial shunt. | Interactive cardiovascular and thoracic surgery | 2014 | Yes |
| The benefits of high-flow management in children with pulmonary atresia. | Artificial organs | 2009 | Yes |
Showing 5 of 14 publications.
Not on this page
Not measured: delivery record.
Checked, with nothing recorded for this condition: serious adverse events in this condition's trials, prevalence, rare-disease identity, and sub-conditions in mesh.
Not computed for conditions with fewer than 10 trials: drugs tested.